To Partner, or Not to Partner: That is the Question

Traditional wisdom holds that biotechnology companies benefit from collaborations with their larger pharmaceutical peers, which can help validate a company’s technology, provide capital to help fund clinical development, and enable access to experienced clinical, regulatory and commercial infrastructure.  While this was certainly true in the early days of biotechnology, the industry has now matured – … Read moreTo Partner, or Not to Partner: That is the Question

Merger Means Billions for Biotechnology?

In March 2009, we asked the question “Where Might Genentech Investors Redeploy $47 Billion?” in response to the news that Roche Holding AG (RHHBY.PK) would acquire the outstanding publicly held interest in Genentech for a total payment of approximately $47 billion in cash.   We hypothesized that investors seeking biotechnology companies of comparable size and liquidity … Read moreMerger Means Billions for Biotechnology?

Biotech Deal Activity a Mixed Bag During Major Conference

Last week, thousands of registrants gathered in San Francisco, California for the JP Morgan Healthcare Conference [JPMHC] to hear 25-minute presentations from 364 life science companies.  For industry executives and investors, deal activity emanating from the annual event typically serves as a good barometer for the rest of the year. Adding to an already hectic … Read moreBiotech Deal Activity a Mixed Bag During Major Conference

Biotech’s Top and Bottom Ten from 2010

At the start of the year, we provided a favorable outlook for the biotechnology industry in 2010 that was based on the same six drivers we proposed for 2009, which included the following: Sector’s defensive characteristics and impact on future economic growth Highest number of annual new product approvals since 2004 Record number of products … Read moreBiotech’s Top and Bottom Ten from 2010

For Biotechnology in 2010, it’s Déjà vu All over Again

“It’s déjà vu all over again” – Yogi Berra With Opening Day less than a month away, it seems only fitting to reference one of the most quoted personalities of our time to describe our analysis of the biotechnology sector in 2010.  In this article, we review our favorable outlook for the industry, draw comparisons … Read moreFor Biotechnology in 2010, it’s Déjà vu All over Again

Biotech Deal Activity Declines…The Pause that Refreshes?

* MD Becker Partners reporting live from the JP Morgan Healthcare Conference This week, nearly 6,500 registrants gathered in San Francisco, California for the JP Morgan Healthcare Conference to hear 25-minute presentations from 338 life science companies.  For industry executives and investors, the annual event serves as a good barometer for the rest of the … Read moreBiotech Deal Activity Declines…The Pause that Refreshes?

2009: Biotech’s Stealth Small Cap Rally

On the heels of the Dow Jones Industrial Average (DJIA) logging its worst annual performance since 1931 and the NASDAQ Composite (COMP) having its worst year since inception in 1971, it may have seemed counter intuitive to provide a bullish outlook for the biotechnology industry in 2009.  Nonetheless, at the start of the year we … Read more2009: Biotech’s Stealth Small Cap Rally